LTB4 Sweden Overview
- Founded
-
2004
- Status
-
Out of Business
- Employees
-
1
- Latest Deal Type
-
Liquidation
LTB4 Sweden General Information
Description
Developer of small molecule intended to target diseases such as infections and cancer. The company's small molecule is made by using arachidonic acid metabolite leukotriene B4 (LTB4) to innate immunity system for targeting diseases, enabling patients to avail enhanced care without any side effects.
Contact Information
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Discovery Tools (Healthcare)
Primary Office
- Kornhamstorg 53
- 111 27 Stockholm
- Sweden
+46 08-442 00 00
LTB4 Sweden Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Bankruptcy: Liquidation | 01-Jul-2017 | Completed | Bankruptcy: Liquidation | |||
| 1. Early Stage VC | Completed | Generating Revenue |
LTB4 Sweden Patents
LTB4 Sweden Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2024316-B9 | Crystalline leukotriene b4 | Inactive | 30-Mar-2006 | 000000000 | |
| EP-2024316-A1 | Crystalline leukotriene b4 | Active | 30-Mar-2006 | 000000000 | |
| EP-2024316-B1 | Crystalline leukotriene b4 | Inactive | 30-Mar-2006 | 000000000 | |
| ES-2392995-T3 | Leukotriene b4 crystalline | Active | 30-Mar-2006 | 000000000 | |
| EP-1840114-A1 | Crystalline leukotriene b4 | Inactive | 30-Mar-2006 | C07C59/42 |
LTB4 Sweden Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Carl-Johan Dalsgaard Ph.D | Managing Director |
LTB4 Sweden Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
